CMH :: Clinical and Molecular Hepatology

REVIEW Current status and strategies for viral hepatitis control in Korea
Viral hepatitis is one of major global health challenges with increasing disease burden worldwide. Hepatitis B virus and hepatitis C virus infections are major causes of chronic liver diseases. They can lead to cirrhosis, hepatocellular carcinoma, and death in significant portio...

REVIEW Current status and strategies for the control of viral hepatitis A in Korea
Hepatitis A virus is one of the most frequent causes of foodborne infection, which is closely associated with sanitary conditions and hygienic practices. The clinical spectrum of acute hepatitis A is wide, ranging from mild case without any noticeable symptoms to severe case wit...

REVIEW Current status and strategies for hepatitis B control in Korea
Hepatitis B virus (HBV) infection is the most common cause of chronic liver diseases in Korea. After the introduction of the universal HBV vaccination program, the prevalence of hepatitis B surface antigen was markedly reduced, and Korea is now classified as an area of intermedi...

ORIGINAL ARTICLE Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?
Background/Aims: Surveillance for hepatocellular carcinoma (HCC) with ultrasound in high-risk populations is generally believed to improve opportunities for treatment. However, tumors are still missed due to various factors. This study explores success versus failure of HCC surv...

Current Issue

Volume 23(3); Sep 2017

Volume 23(2); June 2017

Volume 23(1); March 2017

Volume 22(4); December 2016

Volume 22(3); September 2016

Most-cited are based on citations from 2015 ~ 2017.

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016

Su Jong Yu

Clin Mol Hepatol.2016;22(1):7-17. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.7

Cited By 27

KASL clinical practice guidelines: management of chronic hepatitis B

Clin Mol Hepatol.2016;22(1):18-75. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.18

Cited By 25

Hepatitis C virus-induced hepatocellular carcinoma

Nicolas Goossens, Yujin Hoshida

Clin Mol Hepatol.2015;21(2):105-114. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.105

Cited By 21

The mutational landscape of hepatocellular carcinoma

Ju-Seog Lee

Clin Mol Hepatol.2015;21(3):220-229. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.220

Cited By 15

Personalized management of cirrhosis by non-invasive tests of liver fibrosis

Grace Lai-Hung Wong, Wendell Zaragoza Espinosa, Vicnent Wai-Sun Wong

Clin Mol Hepatol.2015;21(3):200-211. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.200

Cited By 13

Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis

Yoon Ok Jang, Baek Gyu Jun, Soon Koo Baik, Moon Young Kim, Sang Ok Kwon

Clin Mol Hepatol.2015;21(2):141-149. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.141

Cited By 12

Clinical implications of advances in liver regeneration

Yong Jin Kwon, Kyeong Geun Lee, Dongho Choi

Clin Mol Hepatol.2015;21(1):7-13. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.7

Cited By 12

The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease

Goh Eun Chung, Donghee Kim, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Seon Hee Lim, Mustafa Itani

Clin Mol Hepatol.2016;22(1):146-151. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.146

Cited By 12

New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis

Hyun Young Woo, Jeong Heo

Clin Mol Hepatol.2015;21(2):115-121. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.115

Cited By 11

KASL clinical practice guidelines: management of hepatitis C

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol.2016;22(1):76-139. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.76

Cited By 10

The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B

In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim

Clin Mol Hepatol.2015;21(1):32-40. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.32

Cited By 9

Personalized treatment of hepatitis B

Anna S. Lok

Clin Mol Hepatol.2015;21(1):1-6. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.1

Cited By 8

Acute-on-chronic liver failure: a new syndrome in cirrhosis

Richard Moreau

Clin Mol Hepatol.2016;22(1):1-6. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.1

Cited By 7

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir

Han Na Choi, Jeong Eun Song, Hyeon Chul Lee, Hyeong Ho Jo, Chang Hyeong Lee, Byung Seok Kim

Clin Mol Hepatol.2015;21(1):24-31. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.24

Cited By 6

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Jung Gil Park

Clin Mol Hepatol.2015;21(3):287-294. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.287

Cited By 6

Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase

Yasuko Iwakiri

Clin Mol Hepatol.2015;21(4):319-325. Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.319

Cited By 6

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients

Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa

Clin Mol Hepatol.2015;21(1):41-48. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.41

Cited By 6

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong

Clin Mol Hepatol.2015;21(1):49-59. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.49

Cited By 6

Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment

Hyunwoo Oh, Dae Won Jun, Waqar K Saeed, Mindie H Nguyen

Clin Mol Hepatol.2016;22(3):327-335. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0049

Cited By 6

Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease

Chansik An, Youn Ah Choi, Dongil Choi, Yong Han Paik, Sang Hoon Ahn, Myeong-Jin Kim, Seung Woon Paik, Kwang-Hyub Han, Mi-Suk Park

Clin Mol Hepatol.2015;21(3):279-286. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.279

Cited By 5

The Korean Association for the Study of the Liver